<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01251016</url>
  </required_header>
  <id_info>
    <org_study_id>CAPPesq 1011/09</org_study_id>
    <nct_id>NCT01251016</nct_id>
  </id_info>
  <brief_title>Effect of Bariatric Surgery on Gut Hormones Production and Cure of Type 2 Diabetes Mellitus</brief_title>
  <official_title>Changes in Gene Expression of Intestinal Tissue From Type 2 Diabetes Patients Submitted to Roux-en-Y Gastric Bypass</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pennington Biomedical Research Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Federal University of São Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Type 2 diabetes mellitus (T2DM) is a relevant public health problem and obesity has been
      associated as the major risk factor. Roux-en-Y gastric bypass is an effective method to treat
      severe obesity, and its metabolic benefits can lead to early and complete remission of T2DM,
      even before a considerable weight loss. We have hypothesized that intestinal anatomic changes
      may change intestinal genes expression related to glycemic control. The knowledge of
      mechanisms mediating the glycemic control after Roux-en-Y gastric bypass and it site of
      action in bowel may eventually help to develop alternative, less invasive and safer surgery
      for the treatment of T2DM, as well as drug development for the newly targets identified.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2010</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Patient Selection</measure>
    <time_frame>2013</time_frame>
    <description>10 patients fully completed with all biological samples colected in the preoperative and postoperative periods (gastrointestinal tissue). RNA extraction of gastrointestinal samples is being performed.</description>
  </primary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Surgery</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Severe obese patients with T2DM candidates to Roux-en-Y gastric bypass surgery
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Type 2 diabetes mellitus (T2DM) diagnosis Duration of T2DM &gt;5 years Use of oral
        antidiabetic agents Body Mass Index &gt;40 kg/m2 Candidates to Roux-en-Y gastric bypass

        Exclusion Criteria:

        Type 1 diabetes mellitus or non-diabetics Use of insulin Thyroid diseases Candidate to
        other surgery technique Body Mass Index &lt;40 kg/m2 Presence of bacterium H. Pylori
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinics Hospital of the University of São Paulo Medical School</name>
      <address>
        <city>São Paulo</city>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinics Hospital FMUSP</last_name>
      <phone>+55 11 30696000</phone>
      <email>webmaster@hcnet.usp.br</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2010</study_first_submitted>
  <study_first_submitted_qc>November 30, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2010</study_first_posted>
  <last_update_submitted>December 5, 2015</last_update_submitted>
  <last_update_submitted_qc>December 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo</investigator_affiliation>
    <investigator_full_name>Dan Linetzky Waitzberg</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Type 2 diabetes mellitus</keyword>
  <keyword>Y-Roux gastric bypass</keyword>
  <keyword>Gut hormones</keyword>
  <keyword>Gene expression</keyword>
  <keyword>Surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

